GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » La Jolla Pharmaceutical Co (NAS:LJPC) » Definitions » Profitability Rank

La Jolla Pharmaceutical Co (La Jolla Pharmaceutical Co) Profitability Rank : 2 (As of Jun. 2022)


View and export this data going back to 1994. Start your Free Trial

What is La Jolla Pharmaceutical Co Profitability Rank?

La Jolla Pharmaceutical Co has the Profitability Rank of 2. It has had trouble to make a profit.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

La Jolla Pharmaceutical Co's Operating Margin % for the quarter that ended in Jun. 2022 was -10.15%. As of today, La Jolla Pharmaceutical Co's Piotroski F-Score is 7.


Competitive Comparison of La Jolla Pharmaceutical Co's Profitability Rank

For the Biotechnology subindustry, La Jolla Pharmaceutical Co's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


La Jolla Pharmaceutical Co's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, La Jolla Pharmaceutical Co's Profitability Rank distribution charts can be found below:

* The bar in red indicates where La Jolla Pharmaceutical Co's Profitability Rank falls into.



La Jolla Pharmaceutical Co Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

La Jolla Pharmaceutical Co has the Profitability Rank of 2. It has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

La Jolla Pharmaceutical Co's Operating Margin % for the quarter that ended in Jun. 2022 is calculated as:

Operating Margin %=Operating Income (Q: Jun. 2022 ) / Revenue (Q: Jun. 2022 )
=-1.07 / 10.543
=-10.15 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

La Jolla Pharmaceutical Co has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


La Jolla Pharmaceutical Co Profitability Rank Related Terms

Thank you for viewing the detailed overview of La Jolla Pharmaceutical Co's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


La Jolla Pharmaceutical Co (La Jolla Pharmaceutical Co) Business Description

Traded in Other Exchanges
N/A
Address
201 Jones Road, Suite 400, Waltham, MA, USA, 02451
La Jolla Pharmaceutical Co is a biopharmaceutical company. The company's main activity is the discovery, development, and commercialization of innovative therapies that improve patients' life-threatening conditions. The company's portfolio consists of an angiotensin II formulation, which regulates blood pressure; a formulation of hepcidin, an endogenous peptide hormone that regulates iron metabolism; and an antibiotic approved by the U.S. Food and Drug Administration.
Executives
Larry G. Edwards director, officer: Chief Executive Officer C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
David A Ramsay director HALOZYME THERAPEUTICS, INC., 11588 SORRENTO VALLEY ROAD, #17, SAN DIEGO CA 92121
Craig A Johnson director C/O PURE BIOSCIENCE, 1725 GILLESPIE WAY, EL CAJON CA 92020
Michael S Hearne officer: Chief Financial Officer 4747 EXECUTIVE DRIVE SUITE 210 SAN DIEGO CA 92121
Robert Rosen director C/O HERON THERAPEUTICS, INC, 4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO CA 92121
Kevin C Tang director, 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Laura L. Johnson director C/O LA JOLLA PHARMACEUTICAL COMPANY, LA JOLLA VILLAGE DRIVE, SUITE 1070, SAN DIEGO CA 92122
Darryl Wellinghoff officer: Chief Commercial Officer 4550 TOWNE CENTRE COURT SAN DIEGO CA 92121
Lakhmir S Chawla officer: Chief Medical Officer 1960 KIRBY ROAD, MCLEAN VA 22101
Jennifer Carver officer: Sr. Vice President, Operations 725 NEWPORT STREET, DENVER CO 80220
James Rolke officer: Chief Scientific Officer 10182 TELESIS COURT, 6TH FLOOR, SAN DIEGO CA 92121
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
George F Tidmarsh director, officer: President, CEO & Secretary

La Jolla Pharmaceutical Co (La Jolla Pharmaceutical Co) Headlines

From GuruFocus

La Jolla Pharmaceutical Company Announces Share Repurchase Plan

By Business Wire Business Wire 11-17-2021

Innoviva to Acquire La Jolla Pharmaceutical Company

By Business Wire Business Wire 07-11-2022